135 related articles for article (PubMed ID: 29425861)
41. The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?
Poirier A; Portmann R; Cascais AC; Bader U; Walter I; Ullah M; Funk C
Drug Metab Dispos; 2014 Sep; 42(9):1466-77. PubMed ID: 24989889
[TBL] [Abstract][Full Text] [Related]
42. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
43. Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.
Bins S; van Doorn L; Phelps MA; Gibson AA; Hu S; Li L; Vasilyeva A; Du G; Hamberg P; Eskens F; de Bruijn P; Sparreboom A; Mathijssen R; Baker SD
Clin Transl Sci; 2017 Jul; 10(4):271-279. PubMed ID: 28371445
[TBL] [Abstract][Full Text] [Related]
44. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2017 Jun; 120():43-50. PubMed ID: 28288939
[TBL] [Abstract][Full Text] [Related]
45. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
46. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
[TBL] [Abstract][Full Text] [Related]
47. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Shi P; Liao M; Chuang BC; Griffin R; Shi J; Hyer M; Fallon JK; Smith PC; Li C; Xia CQ
Xenobiotica; 2018 Nov; 48(11):1173-1183. PubMed ID: 29098941
[TBL] [Abstract][Full Text] [Related]
48. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
49. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
50. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
51. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
52. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
54. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
Imai Y; Tsukahara S; Asada S; Sugimoto Y
Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
[TBL] [Abstract][Full Text] [Related]
55. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.
An G; Morris ME
Biopharm Drug Dispos; 2010 Jul; 31(5-6):340-50. PubMed ID: 20535833
[TBL] [Abstract][Full Text] [Related]
56. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding JF; Zhong DF
Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
[TBL] [Abstract][Full Text] [Related]
57. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
59. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
Takeuchi R; Shinozaki K; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):68-74. PubMed ID: 26467765
[TBL] [Abstract][Full Text] [Related]
60. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.
Fujita KI; Masuo Y; Yamazaki E; Shibutani T; Kubota Y; Nakamichi N; Sasaki Y; Kato Y
J Pharm Sci; 2017 Sep; 106(9):2632-2641. PubMed ID: 28479358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
